Is Rapport Therapeutics, Inc. (RAPP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 21.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 21.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.5% / 33% | 96.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 21.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.5% / 33% | 96.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -28.2% | |
| Return on Assets (ROA) | -18.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$65M |
| Free Cash Flow | -$67M |
| Total Debt | $1M |
| Debt-to-Equity | 2.4 |
| Current Ratio | 26.2 |
| Total Assets | $315M |
Price & Trading
| Last Close | $29.00 |
| 50-Day MA | $28.09 |
| 200-Day MA | $23.59 |
| Avg Volume | 336K |
|
52-Week Range
$7.73
| |
About Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Rapport Therapeutics, Inc. (RAPP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Rapport Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Rapport Therapeutics, Inc.'s debt ratio?
Rapport Therapeutics, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.5%.
What are Rapport Therapeutics, Inc.'s key financial metrics?
Rapport Therapeutics, Inc. has a market capitalization of $1.3B. Return on equity stands at -28.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.